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Despite improved survival, many preterm infants undergo subsequent neurodevelopmental impairment. To date, no neuroprotec-
tive therapies have been implemented into clinical practice. Erythropoietin, a haematopoietic cytokine used for treatment of
anaemia of prematurity, has been shown to have neuroprotective and neuroregenerative effects on the brain in many experimental
studies. The aim of the study was to assess the effect of recombinant human erythropoietin on the microstructural development of
the cerebral white matter using tract-based spatial statistics performed at term equivalent age. A randomized, double-blind placebo-
controlled, prospective multicentre study applying recombinant human erythropoietin in the ﬁrst 42 h after preterm birth entitled
‘Does erythropoietin improve outcome in preterm infant’ was conducted in Switzerland (NCT00413946). Preterm infants were
given recombinant human erythropoietin (3000 IU) or an equivalent volume of placebo (NaCl 0.9%) intravenously before 3 h of
age after birth, at 12–18 h and at 36–42 h after birth. High resolution diffusion tensor imaging was obtained at 3T in 58 preterm
infants with mean (standard deviation) gestational age at birth 29.75 (1.44) weeks, and at scanning at 41.1 (2.09) weeks. Imaging
was performed at a single centre. Voxel-wise statistical analysis of the fractional anisotropy data was carried out using tract-based
spatial statistics to test for differences in fractional anisotropy between infants treated with recombinant human erythropoietin and
placebo using a general linear model, covarying for the gestational age at birth and the corrected gestational age at the time of the
scan. Preterm infants treated with recombinant human erythropoietin demonstrated increased fractional anisotropy in the genu and
splenium of the corpus callosum, the anterior and posterior limbs of the internal capsule, and the corticospinal tract bilaterally.
Mean fractional anisotropy was signiﬁcantly higher in preterm infants treated with recombinant human erythropoietin than in
those treated with placebo (P5 0.001). We conclude that early recombinant human erythropoietin administration improves white
matter development in preterm infants assessed by diffusion tensor imaging and tract-based spatial statistics.
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Introduction
Despite improved survival of preterm infants, the majority
still go on to develop some degree of neurodevelopmental
impairment later in life (Saigal and Doyle, 2008; Latal,
2009). These neurodevelopmental impairments are asso-
ciated with periventricular white matter injury (Woodward
et al., 2006), which is the most common brain injury
observed in preterm infants. Periventricular white matter
disease is also frequently accompanied by neuronal/axonal
disease, as part of the newly described encephalopathy of
prematurity (Volpe, 2009).
In vivo assessment of this neuronal/axonal disease has
become possible with the development of new diffusion
tensor imaging (DTI) protocols in preterm infants (Huppi
and Inder, 2001; Huppi and Dubois, 2006). DTI is a
well-studied MRI technique that allows in vivo assessment
of biological tissues at a microstructural level. In preterm
infants, DTI studies have revealed lower fractional anisot-
ropy values relative to those in healthy term control
infants (Huppi et al., 1998, 2001; Miller et al., 2002;
Mukherjee et al., 2002; Counsell et al., 2003, 2006;
Partridge et al., 2004; Berman et al., 2005; Anjari et al.,
2007; Dudink et al., 2007; Cheong et al., 2009; Skiold
et al., 2010), indicative of altered white matter
development.
Tract-based spatial statistics (TBSS) is an automated,
observer-independent approach for assessing fractional an-
isotropy in the major white matter tracts on a voxel-wise
basis across groups of subjects (Smith et al., 2006). It has
been applied to investigate cerebral microstructure in pre-
term infants at term equivalent age (Anjari et al., 2007),
revealing group differences based on either clinical details
such as chronic lung disease (Ball et al., 2010; Alexandrou
et al., 2014) or birth weight (Lepomaki et al., 2013) or
additional imaging ﬁndings such as local white matter
abnormalities (Bassi et al., 2011). A recent TBSS study
has shown that cognitive and motor outcome correlate
with fractional anisotropy in the corpus callosum (van
Kooij et al., 2012), suggesting that TBSS of DTI data has
the potential to be used as a surrogate biomarker for subse-
quent neurodevelopmental outcome. In term infants with
perinatal asphyxial encephalopathy, TBSS analysis has
been used to detect the treatment effects of therapeutic
hypothermia in a small group of patients (n = 10 per
group) (Porter et al., 2010), indicating that TBSS may
also be used to evaluate neuroprotective interventions
(Ball et al., 2013).
The high incidence of neurodevelopmental impairment in
this population is reﬂected in the ongoing search for
neuroprotective interventions that can prevent injury or
enhance repair of the immature brain, with the goal of
improving long-term motor and cognitive outcome
(Gonzalez and Ferriero, 2009). However, to date no such
neuroprotective intervention has been implemented into
routine clinical care for preterm infants.
Erythropoietin, a haematopoetic cytokine that was ori-
ginally identiﬁed for its role in erythropoiesis, is widely
used for the treatment of anaemia in premature infants
(Ohlsson and Aher, 2006; Ghezzi et al., 2010).
Erythropoietin has been shown to have neuroprotective
and neuroregenerative effects on the brain (Dame et al.,
2001; Juul, 2004; van der Kooij et al., 2008), and erythro-
poietin receptors are present on neuron progenitors, neu-
rons, astrocytes, microglia, endothelial cells and erythrocyte
progenitors (Juul and Felderhoff-Mueser, 2007).
Erythropoietin has anti-inﬂammatory, anti-excitotoxic,
antioxidant and anti-apoptotic effects on neurons and
oligodendrocytes and promotes neurogenesis and angiogen-
esis, which are essential for injury repair and normal
neurodevelopment (Shingo et al., 2001; Juul, 2012).
The safety of recombinant human erythropoietin (rhEpo)
in preterm infants has been established by two clinical trials
with high dose administration (Fauchere et al., 2008; Juul
et al., 2008a, b). Early high-dose rhEpo is well tolerated,
causing no increased mortality or side effects (Fauchere
et al., 2008, 2012). More recently, erythropoietin adminis-
tration has also be shown to be well tolerated by term
infants with hypoxic ischaemic or post-asphyctic encephal-
opathy (Wu et al., 2012).
One clinical trial of rhEpo for treatment of anaemia of
prematurity reporting on the effect of early rhEpo on neu-
rodevelopmental outcome has been published. The neuro-
developmental outcome of 20 preterm infants treated with
early rhEpo was assessed at 18–24 months of age. No ad-
verse or beneﬁcial effect of rhEpo on outcome could be
shown; however, the erythropoietin treatment group
included more infants with intraventricular haemorrhage
than the control group (Newton et al., 1999; Ohls et al.,
2004).
A large retrospective trial indicated clear beneﬁts of
rhEpo for preterm infants, demonstrating that infants trea-
ted with rhEpo scored signiﬁcantly better in the overall
assessment at school age as well as in the psychological
evaluation (Neubauer et al., 2010). These potential neuro-
protective effects are thought to arise from a putative re-
duction in brain injury, but to date the effects of rhEPO on
cerebral microstructure in preterm infants have not been
established.
The aim of the present study was to assess the effect of
early administration of rhEpo on white matter development
in preterm infants using TBSS.
Materials and methods
Ethical approval was granted by the local ethical committee
(KEK StV-36/04), and the study was approved by the Swiss
drug surveillance unit (Swissmedic, 2005DR3179). The trial is
registered at ClinicalTrials.gov (number NCT00413946). Full
details of the trial protocol can be provided on request. The
members of The Swiss EPO Neuroprotection Trial Group are
listed in Appendix 1.
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Patient selection
Preterm infants in this study represent a subgroup of infants
enrolled in the randomized, double-blind placebo-controlled,
prospective multicentre study entitled ‘Does erythropoetin
improve outcome in preterm infants’ (NCT00413946). All
infants born between 26 and 31 gestational weeks, from
whose parents informed consent could be obtained in the ﬁrst
3 h after birth, were included unless they met exclusion criteria
(presence of a genetically deﬁned syndrome, severe congenital
malformation adversely affecting life expectancy, and severe
congenital malformation adversely affecting neurodevelopment
or prior palliative care). A total of 495 preterm infants were
recruited into the study between 2005 and 2013, of whom 58
infants were excluded for an exclusion criterion and/or death
before term equivalent age (Fig. 1). The primary outcome meas-
ure of this study is neurodevelopmental outcome assessed at 2
and 5 years of age. A secondary outcome measure is brain
injury and development assessed by conventional MRI at term
equivalent age, measured in a subgroup of 165 infants (Leuchter
et al., 2014). For this study, only infants with DTI performed in
Zurich (n = 140) were included. Clinical co-morbidities such as
sepsis (blood culture proven), necrotizing enterocolitis, patent
ductus arteriosus, and chronic lung disease (deﬁned as oxygen
requirement at corrected 36 weeks of gestation) were noted.
Randomization, neuroprotective
intervention and blinding
The treatment protocol was based on the previously published
safety trial (Fauchere et al., 2008). Study medication was ran-
domly assigned to each patient number in a 1:1 allocation
using a computer-based random-number generator. Erythro-
poetin or an equivalent volume of normal saline (NaCl
0.9%) placebo was administered intravenously before 3 h of
age after birth, at 12–18h and at 36–42 h after birth. A single
dose consists of 25 mg (3000 IU) human erythropoietin per
kilogram body weight dissolved in 1ml sterile water. Hospital
staff, parents, the outcome assessors and data analysts were
kept blinded to the allocation.
MRI studies
In Zurich, cerebral MRI was performed with a 3.0 T GE
HD.xt MRI scanner (GE Medical Systems), using an 8-channel
receive-only head coil. All infants were scanned under natural
sleep using a vacuum mattress. Ear plugs (attenuation: 24 dB;
Earsoft; Aearo) and Minimuffs (attenuation: 7 dB; Natus) were
applied for noise protection. Oxygen saturation was monitored
during scanning, and a neonatologist and/or neonatal nurse
were present during the MRI investigation.
The structural MRI protocol included T1-weighted images
acquired with a 3D fast spoiled gradient echo sequence (reso-
lution 0.7  0.7  1.4mm3, repetition time = 5.7ms, echo
time = 2.6ms, inversion time = 750ms, ﬂip angle = 12), and
T2-weighted images acquired with a fast recovery fast spin
echo sequence (resolution 0.7  0.7  1.5mm3, repetition
time = 6600ms, echo time = 126ms). The structural magnetic
resonance images were assessed for brain injury based on a
clinical scoring system which was adapted from Woodward
and colleagues (Woodward et al., 2006; Leuchter et al.,
2014). The assessor was not aware of the group assignment
of the infants.
DTI was performed in a single centre, using a pulsed gradient
spin echo echo planar imaging sequence with echo time = 77ms,
repetition time = 9 s, ﬁeld of view = 18 cm, matrix = 128  128,
slice thickness = 3mm. The diffusion encoding scheme included
21 non-collinear gradient encoding directions with b = 1000 and
four interleaved b = 0 images.
DTI data demonstrating motion artefacts (n = 78) or from
infants with cystic lesions (n = 4) apparent on structural MRI
were excluded from further analysis, resulting in a ﬁnal group
size of 58 infants, of whom 24 were treated with rhEpo and
34 were treated with placebo.
Data analysis
Fractional anisotropy maps were calculated with dtiﬁt and
corrected for eddy current distortions with eddy_correct, part
of the FSL software library (http://www.fmrib.ox.ac.uk/fsl/)
(Smith et al., 2004). The skull was removed from the b0
images using the Brain Extraction Tool (BET) (Smith, 2002)
and the corresponding brain mask was applied to the frac-
tional anisotropy maps. The fractional anisotropy maps from
all infants were then aligned to the most representative frac-
tional anisotropy image from the cohort, using an automated
method implemented in the TBSS pipeline, which applies a
non-linear registration of each fractional anisotropy map to
all other fractional anisotropy images and then selects the frac-
tional anisotropy image with the lowest mean warp displace-
ment score. An age-appropriate diffusion MRI template was
then generated from the average of the normalized fractional
anisotropy maps, aligned to the target image corresponding to
the most representative subject. The non-linear registrations
were performed using FNIRT (Andersson et al., 2007a, b),
which uses a b-spline representation of the registration warp
ﬁeld (Rueckert et al., 1999).
Voxel-wise statistical analysis of the fractional anisotropy
data was carried out using TBSS (Smith et al., 2006). After
alignment of the fractional anisotropy maps to the neonatal
template, a mean image was created and thinned to create a
mean fractional anisotropy skeleton, which represents the cen-
tres of all tracts common to the group. This skeleton was
thresholded at a fractional anisotropy level of 40.15, and
voxel-wise cross-subject statistics were used with Randomise
(v2.1) to test for differences in fractional anisotropy between
infants treated with rhEpo and placebo using a general linear
model, including the gestational age at birth and the corrected
gestational age at the time of the scan as covariates. A statis-
tical threshold of P5 0.05 was applied after family-wise error
(FWE) correction for multiple comparisons following thresh-
old-free cluster enhancement (Smith and Nichols, 2009).
Student’s t-test or the Mann-Whitney test as appropriate for
continuous parameters, and chi-square test or Fisher exact test
as appropriate for categorical parameters were used to assess
differences between clinical and demographic parameters in
the erythropoietin and the placebo group. The Pearson coefﬁ-
cient was used to quantify the linear correlation between con-
tinuous variables. A multiple linear regression model was ﬁtted
to fractional anisotropy, with erythropoietin/placebo as the
determinant of interest and adjusted for gender and corrected
gestational age. All analyses were performed with the statis-
tical software R for windows (R Core Team, 2013).
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Randomized* (n = 495) 
Excluded** (n = 14) 
♦  Not meeting inclusion 
criteria (n = 7) 
♦ Meeting exclusion 
criteria (n = 7) 
MRI in Zurich (n = 66) 
MRI in Geneva (n = 17)
MRI (n = 83) 
No MRI (n = 153) 
♦Died (n = 12) 
♦Centre without MR scanner (n = 85) 
♦Parental refusal (n = 56) 
Received complete treatment (n = 225) 
Received incomplete treatment (n = 11)
MRI (n = 92) 
No MRI (n = 133) 
♦Died (n = 12) 
♦Centre without MR scanner (n = 73) 
♦Parental refusal (n = 48) 
Received complete treatment (n = 215) 
Received incomplete treatment (n = 10) 
MRI in Zurich (n = 74) 
MRI in Geneva (n = 18)
Treatment 
MRI
MRI 
Allocated to receive rhEpo (n = 256) Allocated to receive placebo (n = 239) 
Excluded** (n = 20) 
♦  Not meeting inclusion 
criteria (n = 14) 
♦ Meeting exclusion 
criteria (n = 6) 
Analysed (n = 24) 
♦Excluded from analysis (bad quality 
DTI images (n = 40), cystic lesions (n = 2)  
Analysed (n = 34) 
♦Excluded from analysis (bad quality 
images (n = 38), cystic lesions (n = 2)
Analysis in Zurich 
Figure 1 Flow chart of included infants. *Information about screening prior to randomization is not available; **Following randomization,
which occurred before 3 h of life, exclusion criteria or the non-compliance with inclusion criteria (due to errors in the reporting of gestational
age) were discovered in some infants, and thus they were excluded after randomization. Inclusion criteria: gestational age at birth between 26 and
31 6/7 gestational weeks. Exclusion criteria: presence of a genetically defined syndrome, severe congenital malformation adversely affecting life
expectancy, or known to affect neurodevelopment.
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Results
Patients
The TBSS cohort (n = 58) did not differ from the remaining
infants in the main study (n = 437) with regard to birth
weight, chronic lung disease, sepsis, meningitis, necrotizing
enterocolitis, or retinopathy of prematurity (Table 1).
Infants included in the TBSS study had older mean (SD)
gestational age at birth [n = 58, 29.29 (1.48) weeks] than
the infants in the main study [n = 437, 28.74 (1.8) weeks].
Although this difference was only 3 days it reached statis-
tical signiﬁcance.
Table 2 summarizes the demographic and clinical details
of the two groups. No signiﬁcant differences were found in
corrected gestational age at scanning or in any other neo-
natal or clinical details between the two treatment groups
after randomization.
Magnetic resonance
On the basis of the recently published scoring system
(Leuchter et al., 2014), 33 (56.8%) infants had normal
white matter and 42.2% had abnormal white matter.
Three infants had punctate white matter lesions in the cere-
bellar hemispheres.
Tract-based spatial statisitics
These ﬁndings are provided corrected for gestational age at
birth and corrected gestational age at scanning. Fractional
anisotropy correlated strongly with corrected age at scanning
[Pearson correlation coefﬁcient r = 0.74 (P5 0.001), Fig. 2].
Preterm infants treated with rhEpo demonstrated increased
fractional anisotropy in the genu and splenium of the
corpus callosum, the external capsule, the corona radiata
and centrum semiovale, the anterior and posterior limbs of
the internal capsule, and the corticospinal tract bilaterally
(P5 0.01, corrected; Fig. 3). Fractional anisotropy was sig-
niﬁcantly higher in preterm infants treated with rhEpo than
in those treated with placebo (Fig. 4). There were no voxels
where fractional anisotropy was signiﬁcantly higher in
preterm infants treated with placebo. The multiple linear re-
gression model resulted in an adjusted effect of erythropoietin
on fractional anisotropy of 0.02 (P5 0.001, Table 3). The
amount of variability in fractional anisotropy explained by
the model was 70%. No signiﬁcant differences were found in
radial or axial diffusivity between the two groups.
Gender effect
Gender effects were analysed using a multiple linear regres-
sion model with fractional anisotropy as dependent vari-
able, gender and intervention (rhEpo or placebo) as
independent factors. No signiﬁcant differences were found
in mean fractional anisotropy between male and female
infants (P = 0.46). Furthermore no interaction between
intervention and gender could be shown (P = 0.11).
Clinical co-morbidities
Chronic lung disease (n = 9) correlated with mean frac-
tional anisotropy; however, after adjusting for gestational
age at birth this correlation became insigniﬁcant. Sepsis
(n = 8) and necrotizing enterocolitis (n = 1) showed no sig-
niﬁcant correlation with mean fractional anisotropy.
Discussion
This is the ﬁrst clinical imaging study showing that early
erythropoietin administration can improve white matter de-
velopment in preterm infants. These results are consistent
with experimental imaging data from an immature animal
model showing higher fractional anisotropy values in the
corpus callosum in erythropoietin-treated animals compared
to those treated with placebo (Chatagner et al., 2010). The
results are also consistent with the conventional MRI ﬁnd-
ings showing a reduced risk of white matter and grey matter
injury, white matter signal abnormalities, and periventricular
white matter volume loss (Leuchter et al., 2014).
To date, many experimental studies investigating erythro-
poietin as a neuroprotective strategy in adult and neonatal
models of brain injury have been published, showing
signiﬁcant promising neuroprotective effects (van der Kooij
et al., 2008). One possible mechanism by which erythropoi-
etin may protect against brain injury is by protecting the vul-
nerable pre-oligodendrocytes. Accumulating evidence from
Table 1 Comparison of infants with and without TBSS analysis
Variable Modality No MRI n = 437 TBSS n = 58 P-value
Gender (female) n (%) 192 (44) 22 (38) 0.235
Gestational age (weeks) Mean  SD 28.94  1.8 29.7  1.46 50.001
Birth weight (g) Mean  SD 1176  353 1252  325 0.100
Z-score of birth weight Mean  SD 0.06  0.84 0.22  0.85 0.185
Broncho-pulmonary dysplasia n (%) 53 (11%) 7 (19%) 0.590
Necrotizing enterocolitis n (%) 10 (3%) 6 (3%) 1
Sepsis n (%) 36 (13%) 24 (14%) 0.837
Meningitis n (%) 2 (1%) 1 (1%) 1
Retinopathy of prematurity n (%) 27 (11%) 13 (8%) 0.383
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both human (Haynes et al., 2003; Back et al., 2005; Robinson
et al., 2006) and experimental models (Back et al., 2002,
2005; Volpe, 2008) suggests that pre-oligodendrocytes are
the main cellular target for the periventricular white matter
injury common to preterm infants. Given the putative link
between periventricular white matter injury and subsequent
neurodevelopmental impairment, the pre-oligodendrocytes
represent a promising target for neuroprotective therapies.
In a rat periventricular leukomalacia model, erythropoi-
etin has been shown to protect late oligodendrocyte pro-
genitors from hypoxic-ischaemic (HI) injury (Mizuno et al.,
2008). Erythropoietin also protects oligodendrocytes from
interferon-gamma and lipopolysaccharide toxicity (Genc
et al., 2006), improves white matter development in vivo,
and promotes oligodendrocyte maturation and differenti-
ation in culture (Sugawa et al., 2002). Treatment with
erythropoietin also reduced both the incidence and severity
of brain injury in a neonatal mouse model of moderate
to severe oxidative brain injury (Juul et al., 2008a, b).
Administration of erythropoietin upregulates erythropoietin
receptors and reduces N-methyl D-aspartate receptor-
mediated excitotoxic injury (Keller et al., 2006) and pro-
motes oligodendrogenesis, leading to attenuated white
matter injury with increased neurogenesis after hypoxic-
ischaemic injury (Iwai et al., 2010)
Recently, in the neonatal stroke model it was demon-
strated that multiple erythropoietin treatments resulted in
a shift in subventricular neural stem cells, favouring the
production of neurons and oligodendrocytes in injured
tissue. Less astrogliosis was observed at both early and
late time points, suggesting increased progenitor prolifer-
ation, decreased precursor cell death or a change in cell
fate choice (Gonzalez et al., 2013).
To assess the effect of rhEpo on white matter develop-
ment we investigated the fractional anisotropy from diffu-
sion tensor MRI using TBSS. Fractional anisotropy is a
scalar value independent of the local ﬁbre orientation,
which serves as a marker for white matter tract integrity,
thereby providing a relatively objective and straightforward
measure for comparison across subject groups (Smith et al.,
2006). In this study, fractional anisotropy was calculated
from an estimate of the diffusion tensor at each voxel,
and compared between erythropoietin and placebo
groups using an automated TBSS analysis, as TBSS pro-
vides an objective and reproducible voxel-wise analysis of
the global white matter integrity. Using this approach, we
were able to show that preterm infants treated with
Table 2 Demographic and clinical parameters of the infants
Characteristic Reported results rhEpo group (n = 24) Placebo group (n = 34) P-value
Gestational age (weeks) Mean  SD 30.17  1.44 29.5  1.44 0.095b
Birth weight (g) Mean  SD 1337  332 1192  10 0.098b
Z-score of birth weight (SD) Mean  SD 0.27  0.71 0.19  0.95 072b
Gestational age at MRI (weeks) Mean  SD 40.93 (2.09) 41.33 (2.12) 0.49b
Gender (= female) n (%) 8 (33) 14 (41) 0.61a
Retinopathy of prematurity n (%) 3 (13) 4 (12) 0.77a
Sepsisd n (%) 3 (13) 5 (15) 0.88a
NEC n (%) 0 (0) 1 (3) 0.58a
Mechanical ventilation n (%) 8 (33) 13 (38) 0.46a
Duration of mechanical ventilation (days) Median (range) 0 (0–6) 0 (2–12) 0.73c
Bronchopulmonary diseasee n (%) 2 (8) 5 (14) 0.38a
Postnatal steroids n (%) 2 (8) 0 (0%) 0.17a
Differences of clinical characteristics between groups were evaluated with the chi-square test or the Fisher exact test as appropriate for the categorical variables, and with Student’s t-
test or Mann-Whitney test as appropriate for the continuous variables. SD = standard deviation; IQR = interquartile range (25–75th percentiles); NEC = necrotizing enterocolitis.
aChi-square test or Fisher exact test as appropriate.
bStudent test.
cMann-Whitney test.
d Sepsis proven by positive blood cultures.
eOxygen requirement at corrected age of 36 weeks.
Figure 2 Scatterplot showing the strong positive correl-
ation between fractional anisotropy and corrected gesta-
tional age at imaging.
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erythropoietin have higher fractional anisotropy in most
major white matter tracts compared to those preterm in-
fants treated with placebo. As fractional anisotropy is
largely dependent on axonal thickness, including pre-
myelination oligodendrocyte wrapping and myelination or
axonal attenuation (Sakuma et al., 1991), our results sug-
gest that infants treated with rhEpo have more coherently
bundled, more mature ﬁbres along the axis of greatest
diffusion, likely reﬂecting the protective effects of rhEpo
on reducing white matter injury and on the promotion of
proliferation, maturation and differentiation of pre-
oligodendrocytes. These results conﬁrm the conventional
MRI ﬁndings, with rhEpo treated infants having less
white and grey matter injury, fewer white matter signal
abnormalities and periventricular white matter loss [re-
ported elsewhere by Leuchter et al. (2014) on the entire
multicentre cohort].
Cumulative erythropoietin
Cumulative erythropoietin doses have been shown to pro-
vide superior neuroprotection when compared to single
dose administration following brain injury in a rat model
(Kellert et al., 2007; Gonzalez et al., 2009). This improved
neuroprotection is likely to arise from multiple effects of
erythropoietin during the evolving injury response.
Speciﬁcally, erythropoietin decreases the early inﬂammatory
response, decreases both early and late neuronal apoptosis
Figure 3 Mean fractional anisotropy skeleton (green) overlaid on the mean fractional anisotropy map in the axial and coronal
planes. Regions of the fractional anisotropy skeleton in green represent voxels where there was no difference in fractional anisotropy between
infants treated with erythropoietin and placebo. Voxels demonstrating significantly higher fractional anisotropy in the erythropoietin-treated
group are overlaid in red-yellow.
Figure 4 Effect of erythropoietin treatment. Boxplot
showing the differences in fractional anisotropy (median and inter-
quartile range) between preterm infants treated with erythropoietin
(EPO) and treated with placebo.
Table 3 Results of the linear regression model for
fractional anisotrophy
Coefficient Standard error P-value
Intercept 0.132 0.037 0.001
Epo (versus placebo) 0.019 0.004 _0.001
Gender Male 0.001 0.004 0.793
Corrected gestational age 0.009 0.001 50.001
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(Juul et al., 2008a, b), and stimulates late repair processes
such as neurogenesis, angiogenesis and migration of regen-
erating neurons (Tsai et al., 2006). As the infants in this
study were given rhEpo within 2 days of birth and MRI
was performed after an interval of several weeks, our data
suggest that three early rhEpo doses also improve neuro-
protection for preterm neonates, providing a similar long-
term improvement to that seen in the neonatal stroke
model (Gonzalez et al., 2013). The neuroprotective effect
of erythropoietin may be further enhanced by giving rhEpo
for a longer period than just within the ﬁrst 42 h.
Gender effect
Male preterm infants are known to be at higher risk for
abnormal neurological outcome than female preterm infants.
A recent study has shown that male infants have higher rates
for disability and cognitive delay even after adjustment for
gestational age at birth and birth weight (Peacock et al.,
2012). This observation is in agreement with data from pub-
lished studies showing constitutional differences between
genders, which are not explained by perinatal, neonatal or
postnatal factors (Brothwood et al., 1986; Stevenson et al.,
2000; Hintz et al., 2006). Therefore, we performed a linear
regression to evaluate the interaction between erythropoietin
and gender with respect to the mean fractional anisotropy.
There was no signiﬁcant gender effect on mean fractional
anisotropy in the measured white matter tracts (P = 0.46),
and no signiﬁcant interaction between gender and interven-
tion (rhEpo versus placebo) (P = 0.23), indicating that in our
sample, gender does not signiﬁcantly inﬂuence the effects of
erythropoietin treatment on mean fractional anisotropy.
However, the lack of a statistically signiﬁcant gender effect
may also be due to the small numbers in each subgroup (8
and 14 female infants treated with rhEpo and placebo, re-
spectively, 16 and 20 male infants treated with rhEpo and
placebo, respectively).
A recent study showed that gestational age in itself
was not a strong predictor for adverse brain development
as measured by DTI, and that co-morbidities seem to play
a larger role in brain development than the degree of
prematurity (Bonifacio et al., 2010). In our cohort there
was no correlation between mean fractional anisotropy
and clinical co-morbidities such as sepsis, necrotizing
enterocolitis and chronic lung disease, but this might
be due to the small number of infants in our cohort suffering
from chronic lung disease (15.5% versus 34.6%; Bonifacio
et al., 2010), necrotizing enterocolitis or sepsis (Table 1).
Limitations
One limitation of this study is that the TBSS analysis could
only be performed in a subgroup of infants. As the infants
were scanned under natural sleep, some DTI studies were
incomplete or corrupted by motion artefacts, which made
the data unusable. However, we believe that this subgroup
is representative of the whole study group, as clinical
co-morbidities did not differ between the TBSS and the
main cohort. Another limitation is that the TBSS cohort
was signiﬁcantly older than the infants for whom no ima-
ging was performed. However, as the results did not alter
after applying a family-wise error (FWE) correction for
multiple comparisons following threshold-free cluster en-
hancement with gestational age at birth as covariate, it
seems unlikely that the results are driven by differences in
gestational age. A strength of the study is that the magnetic
resonance scans of the TBSS cohort were acquired in a
single centre; hence, additional variance from between-
scanner effects was eliminated.
At present, the neurodevelopmental outcome of this cohort
is insufﬁcient to be able to determine the precise relationship
betweenmean fractional anisotropy andmotor, cognitive and
language outcome. However, as many studies show good cor-
relation between fractional anisotropy and neurodevelop-
mental outcome (Arzoumanian et al., 2003; van Kooij
et al., 2012) in preterm infants, we speculate that preterm
infants treated with rhEpo will show improved outcome.
The study used a very short dosing regimen (up to 42h
post-birth) in accordance with the experimental data avail-
able at the time of the study design, and therefore did not
take into consideration recent experimental data on extended
chronic erythropoietin treatment (van de Looij et al., 2014).
Conclusion
Early rhEpo administration improves white matter develop-
ment in preterm infants assessed by DTI and TBSS. This
promising result is consistent with similar results in an im-
mature animal model of neuroprotection through erythro-
poietin treatment. Neurodevelopmental follow-up at 2 and
5 years are ongoing to further deﬁne the neuroprotective
effect of erythropoietin.
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Appendix 1
The Swiss EPO
Neuroprotection Trial Group
The following local investigators and hospitals
participated in this study (study sites are listed in alphabetical
order): Aarau: Kinderklinik Kantonsspital Aarau (Georg
Zeilinger, MD; Sylviane Pasquier, MD); Basel:
Universita¨tskinderklinik UKBB (Christoph Bu¨hrer, MD;
Rene´ Glanzmann, MD; Sven Schulzke, MD); Chur:
Abteilung fu¨r Neonatologie, Kantons- und Regionalspital
(Brigitte Scharrer, MD; Walter Ba¨r, MD); Gene`ve: Unite´ de
Ne´onatologie, Clinique de Pe´diatrie HCUG (Riccardo Pﬁster,
MD); Zu¨rich: Klinik fu¨r Neonatologie (Jean-Claude
Fauche`re, MD); Zu¨rich: Zentrum fu¨r MR-Forschung (Ernst
Martin, MD; Ianina Scheer, MD; Hadwig Speckbacher,
MTRA).
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